Carlo Maria Cipolla

Jul 1, 2024 | jacc.org | Massimiliano Camilli |Carlo Maria Cipolla |Susan Dent |Giorgio Minotti

Introduction Since the 1980s, anthracyclines, including doxorubicin, daunorubicin, epirubicin, and idarubicin, have been central to treating various hematologic and solid malignancies, such as Hodgkin lymphoma (HL), non-Hodgkin lymphoma (nHL), acute leukemias, breast cancer (BC), ovarian cancer, and sarcomas.1,2 In clinical practice, the application of anthracyclines is limited by a dose-dependent cardiotoxicity, leading to both systolic and diastolic cardiac dysfunction and, in less common...